The company is building a global pipeline of biosimilars, developments of NCE for Immuno-oncology, and building up a Neutraceuticals portfolio, vaccines, CDMO, and digital healthcare platforms. However, high inflation could decrease margins prompting us to reduce TP to Rs 4,500/share.